Study of the Implantable Artificial Bronchus for Severe Emphysema
This study is testing a new device called the Implantable Artificial Bronchus (IAB) for adults with severe emphysema or COPD (Chronic Obstructive Pulmonary Disease). The IAB is a flexible stent that is placed in the lung to help people with emphysema. Researchers want to see how well the IAB works and if it is safe. To join, you must be at least 22 years old, have a diagnosis of COPD/emphysema, and meet certain health criteria, including not smoking for at least four months. The main way they will measure success is by looking at changes in your lung volume (residual volume) 90 days after the IAB is implanted. The current status of this study is unclear.
- Study design
- This is an open-label study, meaning both you and the researchers will know you are receiving the Implantable Artificial Bronchus. It will involve up to 60 participants across multiple sites in the United States, Europe, and Brazil.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your lung volume will be measured 90 days after the last Implantable Artificial Bronchus is implanted.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Multi Center Study Testing a New Implant for Adults With Severe Emphysema
At a glance
Conditions
Where it's being run
3 sites across 3 statesStudy leadership
- Adnan Majid, MD · PRINCIPAL_INVESTIGATOR · Beth Israel Deaconess Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Absolute change in residual volume (RV)90 days after last IAB is implanted
The primary endpoint is the absolute change in residual volume (RV) from baseline to endpoint as recorded 90-days after the last implant.